JP2008526866A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008526866A5 JP2008526866A5 JP2007550457A JP2007550457A JP2008526866A5 JP 2008526866 A5 JP2008526866 A5 JP 2008526866A5 JP 2007550457 A JP2007550457 A JP 2007550457A JP 2007550457 A JP2007550457 A JP 2007550457A JP 2008526866 A5 JP2008526866 A5 JP 2008526866A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- methyl
- biphenyl
- difluoro
- isonicotinamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 57
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 125000005843 halogen group Chemical group 0.000 claims 26
- 239000000651 prodrug Substances 0.000 claims 16
- 229940002612 prodrug Drugs 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 16
- 239000012453 solvate Substances 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 125000001188 haloalkyl group Chemical group 0.000 claims 13
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000004414 alkyl thio group Chemical group 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000004438 haloalkoxy group Chemical group 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 8
- -1 1H-tetrazolyl Chemical group 0.000 claims 7
- 125000000547 substituted alkyl group Chemical group 0.000 claims 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 6
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 6
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 6
- 125000002971 oxazolyl group Chemical group 0.000 claims 6
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 6
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 6
- 125000003107 substituted aryl group Chemical group 0.000 claims 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 6
- 125000000335 thiazolyl group Chemical group 0.000 claims 6
- 125000003282 alkyl amino group Chemical group 0.000 claims 5
- 125000004663 dialkyl amino group Chemical group 0.000 claims 5
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims 3
- PUTFMOAOKZNUSN-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(2h-tetrazol-5-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2NN=NN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F PUTFMOAOKZNUSN-UHFFFAOYSA-N 0.000 claims 3
- 102000004310 Ion Channels Human genes 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 230000005931 immune cell recruitment Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- NHEMHKBZHHLNLI-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(1,2-oxazol-5-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2ON=CC=2)C)C=C1 NHEMHKBZHHLNLI-UHFFFAOYSA-N 0.000 claims 2
- XKTZWZSXRKNGGM-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(1,3,4-oxadiazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2OC=NN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C XKTZWZSXRKNGGM-UHFFFAOYSA-N 0.000 claims 2
- WIMBOLXNLFZPHG-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(1,3-oxazol-5-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2OC=NC=2)C)C=C1 WIMBOLXNLFZPHG-UHFFFAOYSA-N 0.000 claims 2
- CMXASVOPXKZDOI-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(1,3-thiazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2SC=CN=2)C)C=C1 CMXASVOPXKZDOI-UHFFFAOYSA-N 0.000 claims 2
- WQTHUZBGFPUICL-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(2h-tetrazol-5-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2NN=NN=2)C)C=C1 WQTHUZBGFPUICL-UHFFFAOYSA-N 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000016396 cytokine production Effects 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- ACZGJZKDSJLKPZ-UHFFFAOYSA-N 2,6-difluoro-n-[4-(2-methyl-5-pyridin-2-ylphenyl)phenyl]benzamide Chemical compound CC1=CC=C(C=2N=CC=CC=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F ACZGJZKDSJLKPZ-UHFFFAOYSA-N 0.000 claims 1
- RJOOCBTVZKGDSW-UHFFFAOYSA-N 2,6-difluoro-n-[4-(2-methyl-5-pyridin-3-ylphenyl)phenyl]benzamide Chemical compound CC1=CC=C(C=2C=NC=CC=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F RJOOCBTVZKGDSW-UHFFFAOYSA-N 0.000 claims 1
- DYJBJACFGHRXMH-UHFFFAOYSA-N 2,6-difluoro-n-[4-(2-methyl-5-pyridin-4-ylphenyl)phenyl]benzamide Chemical compound CC1=CC=C(C=2C=CN=CC=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F DYJBJACFGHRXMH-UHFFFAOYSA-N 0.000 claims 1
- YCQQPBDGYUQILO-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methoxy-5-(1,3-oxazol-2-yl)phenyl]phenyl]benzamide Chemical compound COC1=CC=C(C=2OC=CN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F YCQQPBDGYUQILO-UHFFFAOYSA-N 0.000 claims 1
- FRIGRPXYZRZZKE-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(1,3,4-oxadiazol-2-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2OC=NN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F FRIGRPXYZRZZKE-UHFFFAOYSA-N 0.000 claims 1
- PRCNEOSMANURNW-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(1,3,4-thiadiazol-2-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2SC=NN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F PRCNEOSMANURNW-UHFFFAOYSA-N 0.000 claims 1
- ZOHBMCUPFMAUSR-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(1,3-oxazol-2-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2OC=CN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F ZOHBMCUPFMAUSR-UHFFFAOYSA-N 0.000 claims 1
- VNYPBEICPYEHMU-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(1,3-oxazol-4-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2N=COC=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F VNYPBEICPYEHMU-UHFFFAOYSA-N 0.000 claims 1
- JJJUQDROKHOMAQ-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(1,3-oxazol-5-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2OC=NC=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F JJJUQDROKHOMAQ-UHFFFAOYSA-N 0.000 claims 1
- HDILCULZLSYGHY-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(1-methyltetrazol-5-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2N(N=NN=2)C)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F HDILCULZLSYGHY-UHFFFAOYSA-N 0.000 claims 1
- VMGWUJGHNODFSG-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(1h-pyrrol-2-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2NC=CC=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F VMGWUJGHNODFSG-UHFFFAOYSA-N 0.000 claims 1
- FOBDRCIFVMXTIZ-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(2-methyl-1,2,4-triazol-3-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2N(N=CN=2)C)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F FOBDRCIFVMXTIZ-UHFFFAOYSA-N 0.000 claims 1
- LIODNSHJTIDZIW-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(2-methyltetrazol-5-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C2=NN(C)N=N2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F LIODNSHJTIDZIW-UHFFFAOYSA-N 0.000 claims 1
- HEYNONRWYRATQB-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(3-methyl-1,2-oxazol-5-yl)phenyl]phenyl]benzamide Chemical compound O1N=C(C)C=C1C1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1 HEYNONRWYRATQB-UHFFFAOYSA-N 0.000 claims 1
- GYWJWMIPARWTPX-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(4-methyl-1,3-thiazol-2-yl)phenyl]phenyl]benzamide Chemical compound CC1=CSC(C=2C=C(C(C)=CC=2)C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=N1 GYWJWMIPARWTPX-UHFFFAOYSA-N 0.000 claims 1
- DZXZUWXTRUTBAZ-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(4-methyl-5-methylsulfanyl-1,2,4-triazol-3-yl)phenyl]phenyl]benzamide Chemical compound CN1C(SC)=NN=C1C1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1 DZXZUWXTRUTBAZ-UHFFFAOYSA-N 0.000 claims 1
- XGHSASJTYJAMBM-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(5-methyl-1h-pyrazol-3-yl)phenyl]phenyl]benzamide Chemical compound N1N=C(C)C=C1C1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1 XGHSASJTYJAMBM-UHFFFAOYSA-N 0.000 claims 1
- RBKOFVZSWPUDHN-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2NC(=O)ON=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F RBKOFVZSWPUDHN-UHFFFAOYSA-N 0.000 claims 1
- ADNXESORVNANSH-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2SC=C(N=2)C(F)(F)F)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F ADNXESORVNANSH-UHFFFAOYSA-N 0.000 claims 1
- HXUWFCJSAZOUHC-UHFFFAOYSA-N 3,5-difluoro-n-[4-[2-methoxy-5-(1,3-oxazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound COC1=CC=C(C=2OC=CN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=NC=C1F HXUWFCJSAZOUHC-UHFFFAOYSA-N 0.000 claims 1
- IBXFTAMPNIFRLP-UHFFFAOYSA-N 3,5-difluoro-n-[4-[2-methyl-5-(1,3,4-oxadiazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2OC=NN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=NC=C1F IBXFTAMPNIFRLP-UHFFFAOYSA-N 0.000 claims 1
- GGFLWLCIACQRTN-UHFFFAOYSA-N 3,5-difluoro-n-[4-[2-methyl-5-(1,3,4-thiadiazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2SC=NN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=NC=C1F GGFLWLCIACQRTN-UHFFFAOYSA-N 0.000 claims 1
- ABHZATVUDHEZLF-UHFFFAOYSA-N 3,5-difluoro-n-[4-[2-methyl-5-(1,3-oxazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2OC=CN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=NC=C1F ABHZATVUDHEZLF-UHFFFAOYSA-N 0.000 claims 1
- YGSAGYAPEBUCNA-UHFFFAOYSA-N 3,5-difluoro-n-[4-[2-methyl-5-(1,3-thiazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2SC=CN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=NC=C1F YGSAGYAPEBUCNA-UHFFFAOYSA-N 0.000 claims 1
- GUETUBNIKSOXBL-UHFFFAOYSA-N 3,5-difluoro-n-[4-[2-methyl-5-(4-methyl-5-methylsulfanyl-1,2,4-triazol-3-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CN1C(SC)=NN=C1C1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=CN=CC=3F)F)=CC=2)=C1 GUETUBNIKSOXBL-UHFFFAOYSA-N 0.000 claims 1
- NMPQFYMAMREFNS-UHFFFAOYSA-N 3-fluoro-n-[4-[2-methyl-5-(1,3,4-oxadiazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2OC=NN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F NMPQFYMAMREFNS-UHFFFAOYSA-N 0.000 claims 1
- FEUMTZNEZOBMOK-UHFFFAOYSA-N 3-fluoro-n-[4-[2-methyl-5-(1,3,4-thiadiazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2SC=NN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F FEUMTZNEZOBMOK-UHFFFAOYSA-N 0.000 claims 1
- WPCGQXNFVBKJKW-UHFFFAOYSA-N 3-fluoro-n-[4-[2-methyl-5-(1,3-oxazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2OC=CN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F WPCGQXNFVBKJKW-UHFFFAOYSA-N 0.000 claims 1
- QCEDPLCXHVYYHI-UHFFFAOYSA-N 3-fluoro-n-[4-[2-methyl-5-(1,3-oxazol-4-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2N=COC=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F QCEDPLCXHVYYHI-UHFFFAOYSA-N 0.000 claims 1
- PJPOZVMUALBLIM-UHFFFAOYSA-N 3-fluoro-n-[4-[2-methyl-5-(1,3-thiazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2SC=CN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F PJPOZVMUALBLIM-UHFFFAOYSA-N 0.000 claims 1
- MLZFLMBXBPPYEA-UHFFFAOYSA-N 3-fluoro-n-[4-[2-methyl-5-(2-methyl-1,2,4-triazol-3-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2N(N=CN=2)C)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F MLZFLMBXBPPYEA-UHFFFAOYSA-N 0.000 claims 1
- CEIRNGJBZOTXOK-UHFFFAOYSA-N 3-methyl-n-[4-(2-methyl-5-pyridin-3-ylphenyl)phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2C=NC=CC=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C CEIRNGJBZOTXOK-UHFFFAOYSA-N 0.000 claims 1
- GONHYCZCLJNREV-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(1,3,4-thiadiazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2SC=NN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C GONHYCZCLJNREV-UHFFFAOYSA-N 0.000 claims 1
- ZNMMURJWVGDXBJ-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(1,3-oxazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2OC=CN=2)C)C=C1 ZNMMURJWVGDXBJ-UHFFFAOYSA-N 0.000 claims 1
- RWWRLUIPEDCHLY-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(1,3-oxazol-4-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2N=COC=2)C)C=C1 RWWRLUIPEDCHLY-UHFFFAOYSA-N 0.000 claims 1
- AOUOIIJWWFSLCP-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(1-methyltetrazol-5-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2N(N=NN=2)C)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C AOUOIIJWWFSLCP-UHFFFAOYSA-N 0.000 claims 1
- AXNLDNHUWVCRPF-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(3-methyl-1,2-oxazol-5-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound O1N=C(C)C=C1C1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)C)=CC=2)=C1 AXNLDNHUWVCRPF-UHFFFAOYSA-N 0.000 claims 1
- FOHRUTIEUZNDIQ-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(4-methyl-1,3-thiazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CSC(C=2C=C(C(C)=CC=2)C=2C=CC(NC(=O)C=3C(=CN=CC=3)C)=CC=2)=N1 FOHRUTIEUZNDIQ-UHFFFAOYSA-N 0.000 claims 1
- WOUMRZCHSWVQTK-UHFFFAOYSA-N 4-methyl-n-[4-(2-methyl-5-pyridin-2-ylphenyl)phenyl]thiadiazole-5-carboxamide Chemical compound N1=NSC(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=C(C=2)C=2N=CC=CC=2)C)=C1C WOUMRZCHSWVQTK-UHFFFAOYSA-N 0.000 claims 1
- CLGKUTCVDXQFFI-UHFFFAOYSA-N 4-methyl-n-[4-(2-methyl-5-pyridin-3-ylphenyl)phenyl]thiadiazole-5-carboxamide Chemical compound N1=NSC(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=C(C=2)C=2C=NC=CC=2)C)=C1C CLGKUTCVDXQFFI-UHFFFAOYSA-N 0.000 claims 1
- CLQLZLCGPUHVLW-UHFFFAOYSA-N 4-methyl-n-[4-[2-methyl-5-(1,2-oxazol-5-yl)phenyl]phenyl]thiadiazole-5-carboxamide Chemical compound N1=NSC(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=C(C=2)C=2ON=CC=2)C)=C1C CLQLZLCGPUHVLW-UHFFFAOYSA-N 0.000 claims 1
- PTTPWZUIZKXKGY-UHFFFAOYSA-N 4-methyl-n-[4-[2-methyl-5-(1,3-thiazol-2-yl)phenyl]phenyl]thiadiazole-5-carboxamide Chemical compound N1=NSC(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=C(C=2)C=2SC=CN=2)C)=C1C PTTPWZUIZKXKGY-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- JKAOBMCPBFAEQR-UHFFFAOYSA-N methyl 3-[4-[(2,6-difluorobenzoyl)amino]phenyl]-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1 JKAOBMCPBFAEQR-UHFFFAOYSA-N 0.000 claims 1
- UUROVLXVZCQYKJ-UHFFFAOYSA-N methyl 3-[4-[(3,5-difluoropyridine-4-carbonyl)amino]phenyl]-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=CN=CC=3F)F)=CC=2)=C1 UUROVLXVZCQYKJ-UHFFFAOYSA-N 0.000 claims 1
- NOBHVWOAQXWKFL-UHFFFAOYSA-N methyl 3-[4-[(3-fluoropyridine-4-carbonyl)amino]phenyl]-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)F)=CC=2)=C1 NOBHVWOAQXWKFL-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- ZJYHCSIDRMVJCH-UHFFFAOYSA-N n-[4-(2-methoxy-5-thiophen-2-ylphenyl)phenyl]-3-methylpyridine-4-carboxamide Chemical compound COC1=CC=C(C=2SC=CC=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C ZJYHCSIDRMVJCH-UHFFFAOYSA-N 0.000 claims 1
- REPOWMBMZCESPG-UHFFFAOYSA-N n-[4-(5-chloro-2-methoxypyridin-3-yl)phenyl]-2,6-difluorobenzamide Chemical compound COC1=NC=C(Cl)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F REPOWMBMZCESPG-UHFFFAOYSA-N 0.000 claims 1
- FFQDNYZYQQTJCY-UHFFFAOYSA-N n-[4-(5-chloro-2-methoxypyridin-3-yl)phenyl]-3-methylpyridine-4-carboxamide Chemical compound COC1=NC=C(Cl)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C FFQDNYZYQQTJCY-UHFFFAOYSA-N 0.000 claims 1
- BVDBPRBGCAMVIK-UHFFFAOYSA-N n-[4-[2-(dimethylamino)-5-(1,3-oxazol-2-yl)phenyl]phenyl]-3-methylpyridine-4-carboxamide Chemical compound CN(C)C1=CC=C(C=2OC=CN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C BVDBPRBGCAMVIK-UHFFFAOYSA-N 0.000 claims 1
- BIIGGBDTMAWGEQ-UHFFFAOYSA-N n-[4-[2-chloro-5-(1,3-oxazol-2-yl)phenyl]phenyl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2OC=CN=2)Cl)C=C1 BIIGGBDTMAWGEQ-UHFFFAOYSA-N 0.000 claims 1
- VJEMLWSCIVANKS-UHFFFAOYSA-N n-[4-[2-chloro-5-(1,3-oxazol-2-yl)phenyl]phenyl]-3,5-difluoropyridine-4-carboxamide Chemical compound FC1=CN=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2OC=CN=2)Cl)C=C1 VJEMLWSCIVANKS-UHFFFAOYSA-N 0.000 claims 1
- DOIRCJTXASVGPW-UHFFFAOYSA-N n-[4-[2-chloro-5-(1,3-oxazol-2-yl)phenyl]phenyl]-3-methylpyridine-4-carboxamide Chemical compound CC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2OC=CN=2)Cl)C=C1 DOIRCJTXASVGPW-UHFFFAOYSA-N 0.000 claims 1
- FBPZZKCLQCACGD-UHFFFAOYSA-N n-[4-[2-chloro-5-(1,3-thiazol-2-yl)phenyl]phenyl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2SC=CN=2)Cl)C=C1 FBPZZKCLQCACGD-UHFFFAOYSA-N 0.000 claims 1
- RRPPHAPIBOIGBN-UHFFFAOYSA-N n-[4-[2-chloro-5-(1,3-thiazol-2-yl)phenyl]phenyl]-3,5-difluoropyridine-4-carboxamide Chemical compound FC1=CN=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2SC=CN=2)Cl)C=C1 RRPPHAPIBOIGBN-UHFFFAOYSA-N 0.000 claims 1
- CDXPRTPWAIUPGS-UHFFFAOYSA-N n-[4-[2-chloro-5-(1,3-thiazol-2-yl)phenyl]phenyl]-3-fluoropyridine-4-carboxamide Chemical compound FC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2SC=CN=2)Cl)C=C1 CDXPRTPWAIUPGS-UHFFFAOYSA-N 0.000 claims 1
- JOMGPQQJXLLZEM-UHFFFAOYSA-N n-[4-[2-chloro-5-(1,3-thiazol-2-yl)phenyl]phenyl]-3-methylpyridine-4-carboxamide Chemical compound CC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2SC=CN=2)Cl)C=C1 JOMGPQQJXLLZEM-UHFFFAOYSA-N 0.000 claims 1
- KOKVANSMRRJMMS-UHFFFAOYSA-N n-[4-[2-methoxy-5-(1,3-oxazol-2-yl)phenyl]phenyl]-3-methylpyridine-4-carboxamide Chemical compound COC1=CC=C(C=2OC=CN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C KOKVANSMRRJMMS-UHFFFAOYSA-N 0.000 claims 1
- SOOVPSRHNUYTBZ-UHFFFAOYSA-N n-[4-[2-methoxy-5-(1,3-oxazol-5-yl)phenyl]phenyl]-4-methylthiadiazole-5-carboxamide Chemical compound COC1=CC=C(C=2OC=NC=2)C=C1C(C=C1)=CC=C1NC(=O)C=1SN=NC=1C SOOVPSRHNUYTBZ-UHFFFAOYSA-N 0.000 claims 1
- OSZIQZHRROTGTD-UHFFFAOYSA-N n-[4-[5-(5-amino-1,3,4-thiadiazol-2-yl)-2-methylphenyl]phenyl]-2,6-difluorobenzamide Chemical compound CC1=CC=C(C=2SC(N)=NN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F OSZIQZHRROTGTD-UHFFFAOYSA-N 0.000 claims 1
- GEXVQFXUKFJYCI-UHFFFAOYSA-N n-[4-[5-(furan-2-yl)-2-methoxyphenyl]phenyl]-3-methylpyridine-4-carboxamide Chemical compound COC1=CC=C(C=2OC=CC=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C GEXVQFXUKFJYCI-UHFFFAOYSA-N 0.000 claims 1
- PKVFLLHAPLTWRZ-UHFFFAOYSA-N n-[4-[5-[5-(dimethylamino)-1,3,4-thiadiazol-2-yl]-2-methylphenyl]phenyl]-2,6-difluoro-n-methylbenzamide Chemical compound S1C(N(C)C)=NN=C1C1=CC=C(C)C(C=2C=CC(=CC=2)N(C)C(=O)C=2C(=CC=CC=2F)F)=C1 PKVFLLHAPLTWRZ-UHFFFAOYSA-N 0.000 claims 1
- BZUOMZUMVYMSMW-UHFFFAOYSA-N n-[4-[5-[5-(dimethylamino)-1,3,4-thiadiazol-2-yl]-2-methylphenyl]phenyl]-2,6-difluorobenzamide Chemical compound S1C(N(C)C)=NN=C1C1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1 BZUOMZUMVYMSMW-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 0 *C1C=CC(*)=CC1c(cc1)ccc1I* Chemical compound *C1C=CC(*)=CC1c(cc1)ccc1I* 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64217905P | 2005-01-07 | 2005-01-07 | |
| US60/642,179 | 2005-01-07 | ||
| US70784505P | 2005-08-12 | 2005-08-12 | |
| US60/707,845 | 2005-08-12 | ||
| PCT/US2006/000296 WO2006083477A2 (en) | 2005-01-07 | 2006-01-06 | Compounds for inflammation and immune-related uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012100291A Division JP2012176959A (ja) | 2005-01-07 | 2012-04-25 | 炎症及び免疫に関連する用途に用いる化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008526866A JP2008526866A (ja) | 2008-07-24 |
| JP2008526866A5 true JP2008526866A5 (enExample) | 2009-02-19 |
| JP5184891B2 JP5184891B2 (ja) | 2013-04-17 |
Family
ID=36777716
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007550457A Expired - Fee Related JP5184891B2 (ja) | 2005-01-07 | 2006-01-06 | 炎症及び免疫に関連する用途に用いる化合物 |
| JP2012100291A Pending JP2012176959A (ja) | 2005-01-07 | 2012-04-25 | 炎症及び免疫に関連する用途に用いる化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012100291A Pending JP2012176959A (ja) | 2005-01-07 | 2012-04-25 | 炎症及び免疫に関連する用途に用いる化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8202999B2 (enExample) |
| EP (1) | EP1846372B1 (enExample) |
| JP (2) | JP5184891B2 (enExample) |
| KR (2) | KR20140018997A (enExample) |
| AU (1) | AU2006211646B2 (enExample) |
| BR (1) | BRPI0606476A2 (enExample) |
| CA (1) | CA2593550A1 (enExample) |
| IL (1) | IL184445A0 (enExample) |
| MX (1) | MX2007008290A (enExample) |
| NZ (1) | NZ556546A (enExample) |
| TW (1) | TWI441819B (enExample) |
| WO (1) | WO2006083477A2 (enExample) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8802721B2 (en) * | 2005-01-25 | 2014-08-12 | Synta Pharmaceuticals Corp. | Thiophene compounds for inflammation and immune-related uses |
| TWI422376B (zh) | 2005-01-25 | 2014-01-11 | Synta Pharmaceuticals Corp | 用於炎症及免疫相關用途之化合物 |
| WO2007031791A1 (en) * | 2005-09-16 | 2007-03-22 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis c |
| CN101346357B (zh) | 2005-10-25 | 2014-04-02 | 盐野义制药株式会社 | 氨基二氢噻嗪衍生物 |
| US7816535B2 (en) * | 2006-01-25 | 2010-10-19 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
| JP2009528273A (ja) * | 2006-01-25 | 2009-08-06 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連使用用の置換ビアリール化合物 |
| AU2007208239B2 (en) * | 2006-01-25 | 2013-04-18 | Synta Pharmaceuticals Corp. | Substituted aromatic compounds for inflammation and immune-related uses |
| JP5430944B2 (ja) * | 2006-01-31 | 2014-03-05 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連用途のためのピリジルフェニル化合物 |
| EP2001476A4 (en) | 2006-03-20 | 2010-12-22 | Synta Pharmaceuticals Corp | BENZOIMIDAZOLYL-PARAZINE-BASED COMPOUNDS FOR INFLAMMATION USES AND IMMUNE DISORDERS |
| CN101522614B (zh) | 2006-08-09 | 2014-06-25 | 史密丝克莱恩比彻姆公司 | 作为阿片样物质受体的拮抗剂或反向激动剂的化合物 |
| US8779154B2 (en) * | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| AU2007322116B2 (en) * | 2006-11-13 | 2013-01-10 | Synta Pharmaceuticals Corp. | Cyclohexenyl-aryl compounds for inflammation and immune-related uses |
| EP2689780A1 (en) | 2007-04-24 | 2014-01-29 | Shionogi & Co., Ltd. | Intermediates for aminodihydrothiazine derivatives substituted with a cyclic group |
| JP5383483B2 (ja) * | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | アルツハイマー症治療用医薬組成物 |
| TW200914440A (en) * | 2007-08-01 | 2009-04-01 | Synta Pharmaceuticals Corp | Vinyl-aryl derivatives for inflammation and immune-related uses |
| US20120064121A1 (en) * | 2007-08-01 | 2012-03-15 | Synta Pharmaceuticals Corp. | Pyridine compounds for inflammation and immune-related uses |
| US8263641B2 (en) | 2007-09-10 | 2012-09-11 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| AU2008326309C1 (en) | 2007-11-21 | 2015-03-12 | Decode Genetics Ehf | Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders |
| JP2011505341A (ja) * | 2007-11-21 | 2011-02-24 | デコード ジェネティクス イーエイチエフ | 炎症性、心血管およびｃｎｓ障害を治療するビアリールｐｄｅ４抑制剤 |
| US8389567B2 (en) | 2007-12-12 | 2013-03-05 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US8063152B2 (en) * | 2008-03-17 | 2011-11-22 | The Goodyear Tire & Rubber Company | Boron containing functionalizing agent |
| KR101324426B1 (ko) | 2008-06-13 | 2013-10-31 | 시오노기세야쿠 가부시키가이샤 | β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체 |
| EP2321303B1 (en) | 2008-08-27 | 2019-11-27 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US8524763B2 (en) | 2008-09-22 | 2013-09-03 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| WO2010039237A1 (en) * | 2008-10-01 | 2010-04-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| AU2009300318A1 (en) * | 2008-10-01 | 2010-04-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| US8143269B2 (en) | 2008-10-03 | 2012-03-27 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| CN102186841A (zh) * | 2008-10-22 | 2011-09-14 | 盐野义制药株式会社 | 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物 |
| US8618307B2 (en) | 2009-09-16 | 2013-12-31 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US8993612B2 (en) * | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| KR20120104570A (ko) | 2009-12-11 | 2012-09-21 | 시오노기세야쿠 가부시키가이샤 | 옥사진 유도체 |
| JP2013525448A (ja) | 2010-04-27 | 2013-06-20 | カルシメディカ，インク． | 細胞内カルシウムを調節する化合物 |
| US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2011139489A2 (en) | 2010-04-27 | 2011-11-10 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| AU2011293201B2 (en) | 2010-08-27 | 2015-11-05 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| CN103261199A (zh) | 2010-10-29 | 2013-08-21 | 盐野义制药株式会社 | 萘啶衍生物 |
| EP2634188A4 (en) | 2010-10-29 | 2014-05-07 | Shionogi & Co | FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE |
| SG189863A1 (en) | 2010-10-30 | 2013-06-28 | Lupin Ltd | Oxazoline and isoxazoline derivatives as crac modulators |
| CN103608345A (zh) | 2011-04-26 | 2014-02-26 | 盐野义制药株式会社 | 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂 |
| CN103702665B (zh) | 2011-05-03 | 2016-08-17 | 幸讬制药公司 | 用于炎症和免疫相关用途的化合物 |
| WO2012170931A2 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2013022243A2 (ko) * | 2011-08-05 | 2013-02-14 | 동국대학교 산학협력단 | 신규한 바이페닐 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물 |
| WO2013037705A2 (en) | 2011-09-16 | 2013-03-21 | Fovea Pharmaceuticals | Aniline derivatives,their preparation and their therapeutic application |
| WO2013059677A1 (en) | 2011-10-19 | 2013-04-25 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US10252984B2 (en) | 2011-10-27 | 2019-04-09 | Mayo Foundation For Medical Education And Research | Inhibiting G protein coupled receptor 6 kinase polypeptides |
| EP2844656A1 (en) | 2012-05-02 | 2015-03-11 | Lupin Limited | Substituted pyrazole compounds as crac modulators |
| WO2013164769A1 (en) | 2012-05-02 | 2013-11-07 | Lupin Limited | Substituted pyridine compounds as crac modulators |
| WO2014008214A1 (en) * | 2012-07-02 | 2014-01-09 | Biogen Idec Ma Inc. | Biaryl-containing compounds as inverse agonists of ror-gamma receptors |
| WO2014059333A1 (en) | 2012-10-12 | 2014-04-17 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2014065434A1 (en) | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
| TR201302590A2 (tr) * | 2013-03-04 | 2014-09-22 | S Gueniz Kuecuekguezel | Diflunisalden hareketle yeni bileşiklerin sentezi. |
| EP3010586A1 (en) | 2013-06-21 | 2016-04-27 | Lupin Limited | Substituted heterocyclic compounds as crac modulators |
| EP3013810A1 (en) | 2013-06-24 | 2016-05-04 | Lupin Limited | Chromane and chromene derivatives and their use as crac modulators |
| PE20161073A1 (es) * | 2013-11-01 | 2016-10-30 | Novartis Ag | Amino-heteroaril-benzamidas como inhibidores de cinasa |
| WO2015090579A1 (en) * | 2013-12-18 | 2015-06-25 | Grünenthal GmbH | Pyrazolyl-based carboxamides iv |
| WO2015164411A2 (en) | 2014-04-21 | 2015-10-29 | Mayo Foundation For Medical Education And Research | Small molecule inhibitors of g protein coupled receptor 6 kinases polypeptides |
| AR103807A1 (es) | 2015-02-27 | 2017-06-07 | Calcimedica Inc | Tratamiento de la pancreatitis |
| WO2017018751A1 (ko) * | 2015-07-24 | 2017-02-02 | 동국대학교 산학협력단 | Blt 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물 |
| KR101796391B1 (ko) | 2015-07-24 | 2017-11-09 | 동국대학교 산학협력단 | Blt 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물 |
| WO2017024009A1 (en) | 2015-08-03 | 2017-02-09 | Quadriga Biosciences, Inc. | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof |
| JP6738575B2 (ja) | 2015-08-07 | 2020-08-12 | カルシメディカ，インク． | 脳卒中および外傷性脳損傷の処置のためのｃｒａｃチャネル阻害剤の使用 |
| TWI780046B (zh) * | 2016-05-10 | 2022-10-11 | 國立大學法人東京醫科齒科大學 | 炎症促進因子表現抑制劑、其有效成分之篩選方法、對於該方法為有用之表現匣、診斷藥及診斷方法 |
| JP7376873B2 (ja) | 2017-11-09 | 2023-11-09 | 国立大学法人 東京医科歯科大学 | がん促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法 |
| US10766900B2 (en) * | 2017-12-29 | 2020-09-08 | Formosa Laboratories, Inc. | Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof |
| CN113557020A (zh) | 2018-09-14 | 2021-10-26 | 瑞真药业公司 | 包含crac抑制剂和皮质类固醇的组合物及其使用方法 |
| KR20220140515A (ko) | 2020-01-13 | 2022-10-18 | 버지 애널리틱스, 인크. | 치환된 피라졸로-피리미딘 및 그의 용도 |
| EP4121089A4 (en) | 2020-03-20 | 2024-04-10 | Calcimedica, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ACUTE LUNG LESION AND ACUTE RESPIRATORY DISTRESS SYNDROME |
| US12522589B2 (en) | 2020-11-13 | 2026-01-13 | Calcimedica, Inc. | Synthesis of CRAC channel inhibitors |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| GB2273930A (en) | 1992-12-30 | 1994-07-06 | Glaxo Group Ltd | Benzanilide derivatives |
| US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| GB2276161A (en) | 1993-03-17 | 1994-09-21 | Glaxo Group Ltd | Aniline and benzanilide derivatives |
| GB2276163A (en) | 1993-03-17 | 1994-09-21 | Glaxo Group Ltd | Pyridine compounds. |
| IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| EP0874629B1 (en) | 1995-12-21 | 2004-05-19 | Bristol-Myers Squibb Pharma Company | ISOXAZOLINE, ISOTHIAZOLINE AND PYRAZOLINE FACTOR Xa INHIBITORS |
| US6274171B1 (en) * | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| AU730224B2 (en) | 1996-12-23 | 2001-03-01 | Du Pont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| CA2276034A1 (en) | 1996-12-23 | 1998-07-02 | Mimi Lifen Quan | Oxygen or sulfur containing 5-membered heteroaromatics as factor xa inhibitors |
| US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
| US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| US6060491A (en) * | 1997-06-19 | 2000-05-09 | Dupont Pharmaceuticals | 6-membered aromatics as factor Xa inhibitors |
| AU7976998A (en) | 1997-06-19 | 1999-01-04 | Du Pont Merck Pharmaceutical Company, The | (amidino)6-membered aromatics as factor xa inhibitors |
| IL133526A0 (en) | 1997-06-19 | 2001-04-30 | Du Pont Pharm Co | Inhibitors of factor xa with a neutral p1 specificity group |
| US6339099B1 (en) * | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
| WO1999032454A1 (en) | 1997-12-22 | 1999-07-01 | Du Pont Pharmaceuticals Company | Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors |
| ES2232202T3 (es) | 1998-12-23 | 2005-05-16 | Bristol-Myers Squibb Pharma Company | Heterobiciclos que contienen nitrogeno como inhibidores del factor xa. |
| US6545054B1 (en) | 1999-02-11 | 2003-04-08 | Millennium Pharmaceuticals, Inc. | Alkenyl and alkynyl compounds as inhibitors of factor Xa |
| CN1346292A (zh) | 1999-03-11 | 2002-04-24 | 杜邦药品公司 | 凝血因子Xa抑制剂与阿司匹林、组织纤溶酶原激活物(TPA)、GPⅡb/Ⅲa拮抗剂、低分子量肝素或肝素联合用于治疗血栓形成 |
| ES2316383T3 (es) | 1999-09-17 | 2009-04-16 | Millennium Pharmaceuticals, Inc. | Benzamidas e inhibidores relacionados del factor xa. |
| US6632815B2 (en) * | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| NZ517828A (en) | 1999-09-17 | 2003-10-31 | Millennium Pharm Inc | Inhibitors having activity against mammalian factor Xa |
| US6720317B1 (en) * | 1999-09-17 | 2004-04-13 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US6844367B1 (en) * | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| US6329527B1 (en) | 1999-10-21 | 2001-12-11 | Bristol-Myers Squibb Pharma Company | Synthesis of 1,3,5-trisubstituted pyrazoles |
| WO2001032628A1 (en) | 1999-11-03 | 2001-05-10 | Bristol-Myers Squibb Pharma Company | Cyano compounds as factor xa inhibitors |
| KR20020070385A (ko) | 2000-01-29 | 2002-09-06 | 주식회사 엘지씨아이 | 아릴-아미딘을 가진 팩터 Ｘａ 억제제와 그의 유도체, 및그의 프로드럭 |
| DE10008329A1 (de) | 2000-02-23 | 2001-08-30 | Merck Patent Gmbh | Aminosulfonylbiphenylderivate |
| AU2001250783A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| CA2407149C (en) | 2000-04-28 | 2010-10-12 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
| AU2001268711A1 (en) * | 2000-06-23 | 2002-01-08 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
| DE10035144A1 (de) | 2000-07-19 | 2002-01-31 | Merck Patent Gmbh | Cyclische Aminosäurederivate |
| US7283874B2 (en) | 2000-10-16 | 2007-10-16 | Remon Medical Technologies Ltd. | Acoustically powered implantable stimulating device |
| GB0106586D0 (en) | 2001-03-16 | 2001-05-09 | Smithkline Beecham Plc | Novel compounds |
| DE60227794D1 (de) | 2001-04-26 | 2008-09-04 | Eisai R&D Man Co Ltd | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon |
| WO2003005025A1 (en) | 2001-07-03 | 2003-01-16 | Biovitrum Ab | Methods for identifying compounds modulating the activity of ppar-gamma |
| GB0124932D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124928D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| WO2004011427A2 (en) | 2002-07-31 | 2004-02-05 | Smithkline Beecham Corporation | Substituted benzanilides as modulators of the ccr5 receptor |
| US20040029920A1 (en) * | 2002-08-06 | 2004-02-12 | Kuduk Scott D. | 2-(biarylalkyl)amino-3-(heterocyclylcarbonylamino)-pyridine derivatives |
| WO2004056774A2 (en) | 2002-12-19 | 2004-07-08 | Neurogen Corporation | Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators |
| HRP20110180T1 (hr) | 2003-07-23 | 2011-04-30 | Synta Pharmaceuticals Corporation | Spojevi za upotrebu kod upala i upotrebe vezane uz imunitet |
| GB0325031D0 (en) | 2003-10-27 | 2003-12-03 | Novartis Ag | Organic compounds |
| EA011010B1 (ru) | 2004-02-27 | 2008-12-30 | Эмджен, Инк. | Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина |
| MX2007005129A (es) * | 2004-10-27 | 2007-09-11 | Daiichi Sankyo Co Ltd | Compuesto de benceno que tiene 2 o mas sustituyentes. |
-
2006
- 2006-01-06 KR KR1020137034625A patent/KR20140018997A/ko not_active Ceased
- 2006-01-06 BR BRPI0606476-0A patent/BRPI0606476A2/pt not_active IP Right Cessation
- 2006-01-06 NZ NZ556546A patent/NZ556546A/en not_active IP Right Cessation
- 2006-01-06 JP JP2007550457A patent/JP5184891B2/ja not_active Expired - Fee Related
- 2006-01-06 AU AU2006211646A patent/AU2006211646B2/en not_active Ceased
- 2006-01-06 WO PCT/US2006/000296 patent/WO2006083477A2/en not_active Ceased
- 2006-01-06 EP EP06733619.8A patent/EP1846372B1/en not_active Expired - Lifetime
- 2006-01-06 US US11/326,872 patent/US8202999B2/en not_active Expired - Fee Related
- 2006-01-06 KR KR1020077017923A patent/KR20070107022A/ko not_active Ceased
- 2006-01-06 TW TW095100558A patent/TWI441819B/zh not_active IP Right Cessation
- 2006-01-06 MX MX2007008290A patent/MX2007008290A/es active IP Right Grant
- 2006-01-06 CA CA002593550A patent/CA2593550A1/en not_active Abandoned
-
2007
- 2007-07-05 IL IL184445A patent/IL184445A0/en unknown
-
2012
- 2012-04-25 JP JP2012100291A patent/JP2012176959A/ja active Pending
- 2012-05-14 US US13/470,772 patent/US8592486B2/en not_active Expired - Fee Related
-
2013
- 2013-10-15 US US14/053,896 patent/US20140039009A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526866A5 (enExample) | ||
| JP2009525285A5 (enExample) | ||
| JP2009524678A5 (enExample) | ||
| JP2009524677A5 (enExample) | ||
| AU2007208225B2 (en) | Thiazole and thiadiazole compounds for inflammation and immune-related uses | |
| AU2006211646B2 (en) | Compounds for inflammation and immune-related uses | |
| AU2007211276B2 (en) | Pyridylphenyl compounds for inflammation and immune-related uses | |
| JP2009529059A5 (enExample) | ||
| JP2007523905A5 (enExample) | ||
| JP2019517455A5 (enExample) | ||
| JP2007519735A5 (enExample) | ||
| JP2008528520A5 (enExample) | ||
| RU2013139662A (ru) | Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления | |
| CA2484159A1 (en) | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | |
| JP2013505901A5 (enExample) | ||
| RU2012111125A (ru) | N-(1, 2, 5- оксадиазол-3-ил)бензамиды и их применение в качестве гербицидов | |
| RU2005129729A (ru) | Производные гетероарилкарбамоилбензола | |
| JP2006506340A5 (enExample) | ||
| JP2007523142A5 (enExample) | ||
| JP2010540462A5 (enExample) | ||
| CA2684105A1 (en) | Pyridine derivatives | |
| JP2010506825A5 (enExample) | ||
| WO2012047966A4 (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| JP2018507234A5 (enExample) | ||
| JP2013542220A5 (ja) | Ｃｒａｃ調節剤としてのオキサゾリン及びイソキサゾリン誘導体 |